InvestorsHub Logo
Followers 30
Posts 1494
Boards Moderated 1
Alias Born 10/15/2014

Re: None

Thursday, 12/07/2017 9:15:17 AM

Thursday, December 07, 2017 9:15:17 AM

Post# of 42517
The CEO put all of the current shareholder's future in getting the FDA approval of the Changas drug. Thought there might be more to Humanigen. That's what he made it look like. https://ih.advfn.com/p.php?pid=nmona&article=76244219


The Company does not have access to sufficient funds to repay the outstanding obligations under the Credit Agreement that have matured. Accordingly, as previously reported, the Company has been discussing and continues to discuss with its Lenders alternative transactions that might result in the satisfaction of the Company ’ s obligations, including the possible conversion of the term loans into equity of the Company, which might occur at a significant discount to current market prices and be dilutive to the ownership interests of existing stockholders. There can be no assurances that the Lenders will agree to a further extension of the maturity of the Company’s obligations under the term loans, to continue discussing any such alternative transactions or that the Company ultimately will be able to reach agreement with such Lenders on the terms of any alternative transaction. If the Company is unable to reach agreement with its Lenders, it may be required to file for bankruptcy.